Steareth-2 vs Steareth-21: Roles, Blends and Trial Design
Steareth-2 and Steareth-21 can work together. Separate blend ratio from total dose, then qualify the phase, stability evidence and actual ingredient grades.
Steareth-2 and Steareth-21 can be partners in an emulsifier system, rather than alternatives to swap at equal weight. Choose their roles in the complete formula before choosing a ratio. The numbers in the INCI names are not a mixing instruction.
A catalogue label is not the whole emulsifier system
MOS lists Steareth-2 under W/O emulsifiers and Steareth-21 under O/W emulsifiers. These are useful starting classifications. They do not mean that adding Steareth-2 necessarily makes a finished cream water-in-oil, or that Steareth-21 alone will stabilize any oil-in-water formula.
There are documented examples of the two ingredients working together. Croda's Brij S721 product page describes O/W systems using its Steareth-21 grade with Brij S2 and other components. Evonik's TEGO Alkanol S21 P MB page also describes combinations with its Steareth-2 grade. These named commercial examples establish that the roles can be complementary. They are not a tested recipe for MOS ingredients, and their performance claims cannot be transferred to a MOS blend.
For purchasing, therefore, separate two questions: do you need to qualify a different grade of one component, or redesign the emulsifier system? Replacing one ingredient with the other at the same weight changes the system; it is not proof of equivalent supply. A similar-looking white flake is not a formulation-equivalence test either.
Design two different trials, not one confused comparison
Define T = w₂ + w₂₁, where w₂ and w₂₁ are the mass fractions of the two ingredients in the complete formula, expressed on the same basis. Define the Steareth-2 fraction within that blend as f = w₂/T. T and f answer different questions. This notation organizes a trial; it does not prescribe a dose, a ratio or a suitable formula.
| Trial | Deliberate change | Question it can address |
|---|---|---|
| Reference | Retain the reference formula, grades and process; record its qualification status | What does the current system actually do under the agreed evaluation conditions? |
| Ratio trial | Change f while holding T constant | Does the balance between the two components affect the observed response? |
| Total-amount trial | Change T while holding the selected f constant; document the balancing component | Does the total amount affect the response within this particular formulation and rebalance? |
If no qualified formula exists, label the reference as an unqualified development prototype. Screening against it can guide development, but does not establish production-replacement equivalence.
Keep the oil-phase composition, other structuring ingredients, addition sequence, temperature history, mixing equipment and conditioning basis comparable wherever the design permits. When increasing T in a formula expressed as 100%, something else must decrease. State which component balances the formula. If it is water, that water change is part of the experiment; it cannot be silently described as “everything else unchanged.”
Changing both T and f in one trial can be a useful screening experiment, but it cannot isolate the cause of a difference. A thicker sample does not, by itself, show that the ratio was better. Agree the comparison and acceptance criteria before inspecting the samples, rather than selecting a favorable observation afterwards.
Judge the complete emulsion, not its first appearance
Confirm the intended continuous phase with a method suitable for the actual formulation. The O/W and W/O selection guide explains the architecture; the commercial classification of one ingredient does not replace that check. Opacity, initial creaminess or a single viscosity reading cannot establish the continuous phase or storage suitability.
Compare viscosity or texture only after the same defined conditioning period and under the same measurement conditions. Record separation or other unacceptable changes under an agreed stability program. An accelerated screen can reveal a failure; a short screen without visible separation is not a shelf-life validation or a universal pass for transport and storage.
Specify the grade and the evidence in the enquiry
For a Steareth-21 enquiry, identify the intended INCI and commercial grade, the role of the companion Steareth-2, and whether this is a supplier change or a new formulation. Share the oil-phase context, relevant electrolytes and pH, processing constraints, T/f trial basis and acceptance criteria. Request current grade-specific technical and safety documents, then agree the appropriate lot-quality evidence.
Include the sample or order quantity, packaging requirement and destination. The MOS catalogue establishes the offered ingredient families; this article does not establish a MOS-specific blend ratio, a numerical HLB for Steareth-21, a universal addition level or a stability guarantee. A defensible purchase follows a qualified complete formula, rather than treating the two ingredient names as interchangeable specifications.